Literature DB >> 21246347

[Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?].

R Nawroth1, A Hartmann, P J Olbert, A S Merseburger, R Stöhr, R Knüchel, M Retz, S Füssel.   

Abstract

One of the principal objects of the scientific research network "German Bladder Cancer Network" is to consolidate research activities on bladder cancer. An overview about directions of current projects on this research topic was given at the annual meeting of the German Association of Urology in Düsseldorf from September 22 to 25 September 2010. As representatives of the"German Bladder Cancer Network" we summarize and comment on some of the most interesting projects on bladder cancer presented at this meeting. A special focus will be on current developments in the field of uropathology and on different aspects in preclinical research on bladder cancer.

Entities:  

Mesh：

Year:  2011        PMID： 21246347     DOI： 10.1007/s00120-010-2486-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  19 in total

Review 1.  [Update on chemotherapy for bladder cancer. Update 2010].

Authors:  M M Heck; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

2.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

3.  EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis.

Authors:  S S Sidhu; R Nawroth; M Retz; H Lemjabbar-Alaoui; V Dasari; C Basbaum
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

Review 4.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

5.  Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.

Authors:  A Bamias; M J Bowles; T Krausz; G Williams; A A Epenetos
Journal:  Int J Cancer       Date:  1993-07-30       Impact factor: 7.396

Review 6.  TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.

Authors:  H Conroy; N A Marshall; K H G Mills
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

7.  HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.

Authors:  Mario W Kramer; Roozbeh Golshani; Axel S Merseburger; Judith Knapp; Alfredo Garcia; Joerg Hennenlotter; Robert C Duncan; Mark S Soloway; Merce Jorda; Marcus A Kuczyk; Arnulf Stenzl; Vinata B Lokeshwar
Journal:  Eur Urol       Date:  2009-03-31       Impact factor: 20.096

Review 8.  Understanding urothelial carcinoma through cancer pathways.

Authors:  Wolfgang A Schulz
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

9.  EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder.

Authors:  A Brunner; M Prelog; I Verdorfer; A Tzankov; G Mikuz; C Ensinger
Journal:  J Clin Pathol       Date:  2007-06-22       Impact factor: 3.411

10.  Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.

Authors:  Birgit Pfost; Christof Seidl; Michael Autenrieth; Dieter Saur; Frank Bruchertseifer; Alfred Morgenstern; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  J Nucl Med       Date:  2009-10       Impact factor: 10.057
View more
  2 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  [Bladder cancer in focus: update 2012 of the German Bladder Cancer Association].

Authors:  B Keck; A S Merseburger; R Stöhr; S Füssel; M J Hoffmann; S Schmid; P Olbert; A Hartmann; R Nawroth
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.